VEGFA and papilloma: Treatment with the vascular endothelial growth factor (VEGF) monoclonal antibody bevacizumab or programmed death-pathway immune checkpoint blockade monotherapy can reduce papilloma disease burden but does not appear to induce immunological clearance of the underlying viral infection2,3.